Korean red ginseng extract,
does it really help with Improved IIEF erectile function and intercourse satisfaction in men with erectile dysfunction?
research showsKorean red ginseng is rated C because it may produce a small statistical increase in IIEF scores, but the average improvement falls below a minimal clinically important difference. A 2021 Cochrane review of nine trials and 587 men reported mean differences of 3.52 for the IIEF-15 erectile-function domain and 2.39 for IIEF-5, below the assumed minimal clinically important differences of 4 and 5. Evidence certainty was low and follow-up extended only to 12 weeks. Multiple randomized trials nevertheless point in the same direction, so the grade is not D but the low end of C with 41 points. This endpoint differs from immune-function verdict 004.
ads claimMarketing turns a small average questionnaire change and some self-reported responses into an effect comparable with prescription erectile-dysfunction treatment. The synthesis instead indicates clinically trivial average IIEF improvement and does not support replacing diagnostic evaluation or established therapy.
Useful facts when choosing a product
- Erectile-dysfunction trials used different red-ginseng preparations and doses; some administered 900 to 1,000 mg three times daily for up to 12 weeks.
- Ginsenoside composition, concentration, and manufacturing differ among products, so results from one preparation cannot automatically be applied to every extract, concentrate, or capsule.
- Single-ingredient ginseng is generally tolerated, but headache, gastrointestinal upset, and insomnia can occur, and blood pressure or glucose may be affected.
- People taking warfarin or other anticoagulants or antiplatelet medicines, antihypertensives, or glucose-lowering drugs should review possible interactions with a clinician.
What the research actually shows
The 2021 Cochrane review by Lee and colleagues included nine studies and 587 men with mild to moderate erectile dysfunction. Mean differences of 3.52 on the IIEF-15 erectile-function domain and 2.39 on IIEF-5 were statistically positive but below their respective minimal clinically important differences; the IIEF-15 intercourse-satisfaction mean difference of 1.19 was also judged trivial. Jang and colleagues in 2008 reviewed seven red-ginseng trials and reported an overall response RR of 2.40, while emphasizing very low methodological quality and limited sample size. A 60-man trial by de Andrade and colleagues in 2007 used 1,000 mg three times daily and reported IIEF-5 and global erectile improvement, but it was small and short. No direct comparison with a phosphodiesterase-5 inhibitor was identified. This is a separate efficacy axis from immune verdict 004.
Why this is classified as C (41)
Several placebo-controlled trials and meta-analyses repeatedly point in a positive direction, so the verdict is not D. In the current Cochrane review of nine trials and 587 men, however, the IIEF-15 mean difference of 3.52 was below the minimal clinically important difference of 4, and the IIEF-5 mean difference of 2.39 was below the threshold of 5. Low certainty, follow-up of no more than 12 weeks, small samples, subjective endpoints, and preparation heterogeneity yield the low end of C with 41 points. Insomnia, gastrointestinal effects, blood-pressure effects, and anticoagulant interactions are separate safety considerations.
Counterpoint. An individual with mild erectile dysfunction may perceive benefit. Erectile dysfunction can also signal cardiovascular disease, diabetes, medicine effects, hormonal disease, or psychological factors, so diagnostic assessment and established treatment should not be delayed.
Rejudgment record. Cross-check revision — Accepted statistical signals across multiple small placebo-controlled trials and meta-analyses, but assigned the low end of C under rule ① because the current Cochrane mean effects on IIEF and intercourse satisfaction were below minimal clinically important differences, certainty was low, and no direct comparison with established therapy exists
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement in the IIEF erectile-function domain | C | IIEF-15 MD 3.52 and IIEF-5 MD 2.39 were statistically positive but below their respective minimal clinically important differences. |
| Improvement in intercourse satisfaction | C | The IIEF-15 intercourse-satisfaction mean difference was 1.19, positive but clinically trivial and based on low-certainty evidence. |
| Improvement in self-reported ability to have intercourse | C | Six studies gave RR 2.55, but they were small and short, used a subjective outcome, and did not compare ginseng directly with a phosphodiesterase-5 inhibitor. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Lee HW et al. 2021 Cochrane review | Systematic review and meta-analysis of randomized and quasi-randomized trials | 587 | Academic Cochrane review; some authors disclosed support related to the Korea Institute of Oriental Medicine | IIEF-15 erectile function, IIEF-5, ability to have intercourse, intercourse satisfaction, and adverse events | IIEF-15 MD 3.52 and IIEF-5 MD 2.39 were statistically positive but below minimal clinically important differences, while intercourse-satisfaction MD 1.19 was also trivial. | Key current synthesis |
| Jang DJ et al. 2008 | Systematic review and meta-analysis of red-ginseng randomized trials | 349 | Academic research; no specific manufacturer funding stated in the public abstract | Overall erectile-dysfunction response and sexual-function questionnaires | Overall response favored red ginseng with RR 2.40 versus placebo, but primary-study methodological quality and total sample size were too low for firm conclusions. | Positive direction with major quality limitations |
| de Andrade E et al. 2007 | Randomized double-blind placebo-controlled trial | 60 | Funding source not stated in the public abstract | IIEF-5, global efficacy question, and adverse events | Korean red ginseng at 1,000 mg three times daily improved IIEF-5 and the global erectile response, but this was a short trial of 60 men. | Direct positive small randomized trial |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-21).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Korean red ginseng extract x improved IIEF and intercourse satisfaction in erectile dysfunction — Evidence Grade C·41. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/korean-red-ginseng-erectile-function-intercourse-satisfaction/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.